[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

2014 Analysis of the Japanese Hospital Tumor Marker Testing Market

November 2013 | 537 pages | ID: 2B51A5201DFEN
Venture Planning Group

US$ 3,880.00 US$ 4,850.00 -20 %

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This new report from Venture Planning Group contains 537 pages, 42 tables and presents a comprehensive analysis of the Japanese hospital tumor marker testing market, including:
  • Major issues pertaining to the Japanese hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.
  • Mortality statistics and scientific views on the etiology of major types of cancer, e. g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.
  • Test volume and sales forecasts for 40 tumor markers performed in Japanese hospitals.
  • Current instrumentation technologies and feature comparison of leading analyzers.
  • Sales and market shares of leading suppliers.
  • Emerging diagnostic technologies and their potential market applications.
  • Product development opportunities.
  • Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.
  • Business opportunities and strategic recommendations for suppliers.
Contains 537 pages and 42 tables
INTRODUCTION

WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. Cancer Statistics and Etiology
  1. Brest Cancer
  2. Lung Cancer
  3. Colon and Rectum Cancer
  4. Prostate Cancer
  5. Stomach Cancer
  6. Leukemia
  7. Lymphoma
  8. Oral Cancer
  9. Skin Cancer
  10. Uterine Cancer
  11. Ovarian Cancer
  12. Bladder Cancer
B. Major Current And Emerging Cancer Diagnostic Tests
  1. Introduction
  2. Tumor Marker Classification
  3. ACTH
  4. Alpha-Fetoprotein (AFP)
  5. Beta-2 Microglobulin
  6. CA 15-3/27. 29
  7. CA 19-9
  8. CA-125
  9. Calcitonin
  10. Carcinoembrionic Antigen (CEA)
  11. Estrogen and Progesterone Receptors
  12. Ferritin
  13. Gastrin
  14. Human Chorionic Gonadotropin (HCG)
  15. Insulin
  16. NSE
  17. Occult Blood
  18. PAP Smear/HPV
  19. Prostatic Acid Phosphatase (PAP)
  20. Prostate-Specific Antigen (PSA)
  21. Squamous Cell Carcinoma Antigen (SCC)
  22. T and B Lymphocytes
  23. TdT
  24. Thyroglobulin
  25. Tissue Polypeptide Antigen (TPA)
  26. Biochemical Tumor Markers
    ADA
    B-Protein
    PNP
    5'-Nucleotidase
  27. Oncogenes
    Abl/abl-bcr
    AIB1
    BCL-2
    BRCA1
    CD44
    C-fos
    C-myb
    C-myc
    CYP-17
    Erb-B
    HPC1
    N-myc
    P40
    P51
    P53
    PIK3CA
    PTI-1
    Ras
    Reg
    Sis
    Src
  28. Polypeptide Growth Factors
    Basic Fibroblast Growth Factor
    Beta-TGF
    Cachectin (TNT)
    Calmodulin
    ECFR
    Nerve Growth Factor (NGF)
    Epidermal Growth Factor (EGF)
    Ornithine Decarboxylase
    Transferrin
    Transforming Growth Factor-Alpha
  29. Ectopic Hormones
  30. Colony Stimulating Factors
  31. Lymphokines
    Alpha-Interferon
      B Cell Growth Factors
      B Cell Growth Factor (BCGF)
      Gamma-Interferon
      Interleukin-1 (IL-1)
      Macrophage Activating Factor
  32. Immunohistochemical Stains
  33. Emerging Tumor Markers
    N-Acetylglucosamine
      Actin
      Alpha-Actin
      Antineuronal Antibodies
      7B2
      B72. 3
      Bax
      BCD-F9
      BLCA-4
    Blood Group Antigens A,B,H
    CA 50
    CA 72-4/TAG-72
    CA 195
    CA-242
    CA-549
    CAM 26
    CAR-3
    Cathepsin-D
    Chromogranin A and B
    Cluster 1 Antigen
    Cluster-5/5A Antigen
    CTA
    CU18
    DR-70
    DU-PAN-2
    Endometrial Bleeding Associated Factor
    Endostatin
    Epithelial Membrane Antigen
    Feulgen Hydrolysis
    Fibronectin
    FSH
    (1->3)-L-fucosyltransferase
    Gastrin-Releasing Peptide (GRP)
    GDCFP-15
    Glucagon
    Glycoamines
    H23
    Her-2
    Human Carcinoma Antigen
    HPA
    HSP27
    Intermediate Filaments
    Cytokeratins/CK18/Cyfra 21-1
    Desmin
    Gliofibrillary Acid Protein
    Neurofilaments
    Vimentin
    KA 93
    Kinases
    KP16D3
    LAI
    Leukocyte Common Antigen
    Lewis Antigens
    Lysophosphatidic Acid (LPA)
    Ma 695/Ma 552
    MABDF3
    MAG
    ME1
    Minactivin
    MN/CA9
    MSA
    Mucin Cancer Antigen (MCA)
    Multiple Tumor Suppressor 1
    Myosin
    NEA-130
    NMP22
    OA-519
    Opiod Peptides
    P-glycoprotein
    Pancreatic Oncofetal Antigen (POA)
    Placental Lactogen
    PR92
    Proliferative Index, Ki-67
    Px
    RB Inactivation/Deletion
    Ret
    SCCL 175
    Selectin
    Sialic Acid
    Sialyl SSEA-1/SLX
    SN10
    Somatostatin
    TA-90
    TABA
    Tachykinin
    TAG 12
    TPS
    Troponin
    Tubulin
    VCAM
    VEGF
    Villen
C. Instrumentation Review And Market Needs
  1. Abbott AxSYM
  2. Abbott Architect c4000
  3. Abbott Architect i2000 Series
  4. Abbott Architect ci8200 System
  5. Beckman Coulter UniCel Series
  6. Beckman Coulter Access
  7. Binding Site ESP600
  8. bioMerieux Mini Vidas
  9. Carolina Chemistries BioLis 24i
  10. DiaSorin Liaison
  11. Horiba ABX Pentra 400
  12. Inverness DS2
  13. J&J Vitros ECi/ECiQ
  14. J&J Vitros 3600
  15. J&J Vitros 5600
  16. Olympus AU5400
  17. Olympus AU3000i
  18. Olympus AU2700
  19. Roche Modular Analytics
  20. Roche Cobas Integra 400
  21. Roche Cobas Integra 400 Plus
  22. Roche Elecsys
  23. Roche Cobas c311
  24. Siemens ADVIA Centaur
  25. Siemens Dimension
  26. Siemens Dimension RxL Max
  27. Siemens Dimension Vista 500
  28. Siemens Immulite
  29. Siemens Stratus
  30. Tosoh AIA-Series
  31. Vital Diagnostics ATAC 8000
  32. Vital Diagnostics Envoy 500
D. Current and Emerging Technologies
  1. Monoclonal and Polyclonal Antibodies
  2. Immunoassays
    a. Technological Principle
    b. Radioimmunoassay (RIA)
    c. Enzyme Immunoassays (EIA)
      Overview
      ELISA
      Immunofiltration
      Particle-Membrane Capture Immunoassay
      Enzyme Amplification
    d. Fluorescent Immunoassays
    e. Luminescence
      Chemiluminescence
      Bioluminescence
    f. Latex Agglutination
    g. Immunoprecipitation
    H. Affinity Chromatographu
    e. Liposome Flow-Injection Immunoassay
  3. Molecular Diagnostics
    a. Technology Overview
    b. Amplification Methods
      PCR
      DAP-PCR
      Immuno-PCR
      QC-PCR
      CAR
      DNA
      HPA
      LCR
      NASBA
      QBR
      SDA
      3 SR, and others
  4. Chromosome Analysis
    a. Chronic Myelogenous Leukemia (CML)
    b. Acute Myeloid Leukemia (AML)
    c. Acute Lymphoblastic Leukemia (ALL)
    d. Malignant Lymphomas Lymphoid Malignancies
    e. Chronic Lymphocytic Leukemia (CLL)
    f. Solid Cancers
    g. Chromosomal Translocation and Oncogenes
  5. Artificial Intelligence
  6. Flow Cytometry
  7. Two Dimensional Gel Electrophoresis (2-DGE)
  8. Biosensors
  9. Competing/Complementing Technologies
    a. CT
    b. MRI
    c. NMR
    d. PET
    e. Photonics Spectroscopy
E. Personal Testing

JAPAN

A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers

MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products

DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

ALTERNATIVE MARKET PENETRATION STRATEGIES

A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
  1. Marketing Approaches
  2. Product Complexity
  3. Customer Preference
  4. Established Suppliers
  5. Emerging Suppliers
  6. Major Types of Distributors
  7. Market Segmentation Factor

POTENTIAL MARKET ENTRY BARRIERS AND RISKS

A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

COMPETITIVE PROFILES

Abbott
AdnaGen
Applied Gene Technologies
Arca
Beckman Coulter/Danaher
Becton Dickinson
Biomedical Diagnostics bioMerieux
Bio-Rad
Cepheid
Correlogic Systems
Dako
Decode
Diadexus
Diagnocure
Diasorin
Eiken Chemical
Enterix
Enzo Biochem
Epigenomics
Exact Sciences
Fujirebio
Gen-Probe
Guided Therapeutics
Hologic
Ipsogen
Kreatech
Kyowa Medex
Life Technologies
Mackay Life Sciences
Myriad Genetics
Nanogen Elitech
OncoLab
Otho-Clinical Diagnostics
Panacea Pharmaceuticals
Polartechnics
Polymedco
PreMD
Qiagen
Radient Pharmaceuticals
Roche
Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Tosoh
Veridex
Wako Pure Chemicals
Wallac/PE
Zila

APPENDIXES

APPENDIX I: MAJOR UNIVERSITIES AND RESEARCH

CENTERS DEVELOPING CANCER DIAGNOSTIC

TECHNOLOGY AND APPLICATIONS

APPENDIX II: ASSUMED CURRENCY EXCHANGE RATES

LIST OF TABLES

Tumor Marker Classification Major Companies Developing or Marketing ACTH Tests
Major Companies Developing or Marketing AFP Tests
Major Companies Developing or Marketing Beta-2 Microglobulin Tests
Major Companies Developing or Marketing CA 15-3/27. 29 Tests
Major Companies Developing or Marketing CA 19-9 Tests
Major Companies Developing or Marketing CA 125 Tests
Major Companies Developing or Marketing Calcitonin Tests
Major Companies Developing or Marketing CEA Tests
Major Companies Developing or Marketing Estrogen Receptor Tests
Major Companies Developing or Marketing Progesterone Receptor Tests
Major Companies Developing or Marketing Ferritin Tests
Major Companies Developing or Marketing Gastrin Tests
Major Companies Developing or Marketing HCG Tests
Major Companies Developing or Marketing Insulin Tests
Major Companies Developing or Marketing NSE Tests
Major Companies Developing or Marketing Occult Blood Tests
Major Companies Developing or Marketing PAP Smear/HPV Tests
Major Companies Developing or Marketing PAP Tests
Major Companies Developing or Marketing PSA Tests
Major Companies Developing or Marketing Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications In Cancer
Diagnosis Oncogenes Potential Applications In Cancer
Diagnosis Major Companies Developing or Marketing Oncogene Tests
Growth Factors Potential Applications In Cancer
Diagnosis Colony Stimulating Factors Potential Applications in Cancer
Diagnosis Lymphokines Potential Applications In Cancer
Diagnosis Immunohistochemical Stains Potential Applications in Cancer Diagnosis
Executive Summary Table: Japan, Hospital Cancer Diagnostic Test Volume and Sales Forecast
Japan, Estimated Cancer Death Rates Per 100,000 Population
Japan, Hospital Laboratories Performing Cancer Diagnostic Tests
Japan, Hospital Laboratories Performing Cancer Diagnostic Tests by Bed Size
Japan, Hospital Laboratories Major Cancer Diagnostic Test Volume Forecast by Test
Japan, Hospital Laboratories Cancer Diagnostic Sales Forecast by Test
Japan, Total Cancer Diagnostics Sales by Major Supplier
Japan, AFP Testing Market Diagnostics Sales by Major Supplier
Japan, CA 15-3/27. 29 Testing Market Diagnostics Sales by Major Supplier
Japan, CA 19-9 Testing Market Diagnostics Sales by Major Supplier
Japan, CA 125 Testing Market Diagnostics Sales by Major Supplier
Japan, Calcitonin Testing Market Diagnostics Sales by Major Supplier
Japan, PAP Testing Market Diagnostics Sales by Major Supplier
Japan, PSA Testing Market Diagnostics Sales by Major Supplier


More Publications